Pipeline

HER2

Human epidermal growth factor receptor 2 (HER2) has been implicated in several aggressive cancers such as in about 62% of glioblastoma multiforme patients ^(1,2), a typically incurable brain tumor, and in about 20% of breast cancer patients ^(3,4). It is also expressed in several other cancers. Glioblastoma multiforme is expected to impact approximately 16,000 patients ⁽⁵⁾, and HER2 positive breast cancer is expected to impact approximately 54,000 patients ⁽⁶⁾, in the US in 2018.

BCMA and Multiple Myeloma

Survival of plasma cells is regulated by B cell maturation antigen (BCMA). Multiple myeloma is a plasma cell disorder that remains an incurable disease, despite recent therapeutic advances. Multiple myeloma is expected to impact approximately 31,000 patients in the US in 2018 ⁽⁷⁾.

References:

(1) J Natl Cancer Inst. 2015 Dec 6;108(5)
(2) J Neurooncol. 2007 Dec;85(3):281-7
(3) http://www.lbbc.org/sites/default/files/HER2%20Final%202016.pdf
(4) Oncologist. 2009 Apr;14(4):320-68
(5) Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
(6) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf
(7) https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html